Join the Postmenopausal Symptoms group to help and get support from people like you.
Postmenopausal Symptoms News (Page 5)
Fezolinetant Safe, Effective for Moderate-to-Severe Menopause Hot Flashes
MONDAY, May 20, 2024 – Fezolinetant is safe and effective for moderate-to-severe vasomotor symptoms (VMS), according to a study presented at the annual European Congress of Endocrinology, hosted by...
Risk for Depressive Symptoms Increased for Perimenopausal Women
THURSDAY, May 9, 2024 – Perimenopausal women have an increased risk for depressive symptoms and diagnoses, according to a review published in the July 15 issue of the Journal of Affective Disorders....
Hormonal Meds for Birth Control, Menopause Linked to Brain Tumors
THURSDAY, March 28, 2024 – The contraceptive injection Depo-Provera and two drugs used for menopause relief could be linked to a heightened risk for brain tumors in some women, a new study warns....
FDA Approves Osphena (ospemifene) for Moderate to Severe Vaginal Dryness Due to Menopause
BLAINVILLE, QC, January 29, 2019 – Duchesnay Inc., a pharmaceutical company specializing in women’s health, announced today that the FDA has approved its supplemental New Drug Application (sNDA) see...
FDA Approves Bijuva (estradiol and progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause
BOCA RATON, Fla.--(BUSINESS WIRE)--Oct. 29, 2018-- TherapeuticsMD, Inc, an innovative women’s healthcare company, today announced that the United States Food and Drug Administration (FDA) has a...
FDA Approves Intrarosa (prasterone) for Postmenopausal Women Experiencing Dyspareunia
November 17, 2016 – The U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of...
Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle
Miami, FL and New York, NY, – September 24, 2014 – Noven Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication with a new dose of...
FDA Approves Brisdelle - First Non-Hormonal Treatment for Hot Flashes Associated with Menopause
June 28, 2013 --The U.S. Food and Drug Administration today approved Brisdelle (paroxetine) to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which...
FDA Approves Osphena for Postmenopausal Women Experiencing Dyspareunia
February 26, 2013 – The U.S. Food and Drug Administration today approved Osphena (ospemifene) to treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom...
FDA Medwatch Alert: Compounded Menopause Hormone Therapy Drugs
[Posted 01/10/2008] FDA informed healthcare professionals and patients that the Agency sent letters warning seven pharmacy operations that the claims they make about the safety and effectiveness of...
Further information
Related condition support groups
Atrophic Vaginitis, Menopausal Disorders
Related drug support groups
gabapentin, Paxil, paroxetine, estradiol, Premarin, Estrace, desvenlafaxine